Cheplapharm, a manufacturer of pharmaceutical products, completed the acquisition of a portfolio of select prescription products from Takeda Pharmaceutical, a pharmaceutical company, for $562m. “These divestments represent another important milestone in our portfolio simplification and optimization strategy as we position Takeda for continued success across our five key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience. We are pleased to have found a partner in Cheplapharm who shares our commitment to patient care and has the experience and resources to continue investing in these important products well into the future for the benefit of patients," Giles Platford, Takeda President.